Drug intelligence / Profile preview

AVR-25

Development stage: Preclinical
Lead developer: AyuVis Research
Modality: Small Molecules
Administration: Intravenous

Overview

AVR-25 is a preclinical-stage small molecule immunotherapy being developed by AyuVis Research. It is a chitin-derived oligosaccharide analog that acts as a potent antagonist of Toll-like receptor 4 (TLR4), with a reported IC50 of 0.15 μM. By modulating the TLR4 pathway, AVR-25 aims to control the excessive inflammatory response associated with acute and chronic conditions. The drug is currently being investigated for the treatment of Bronchopulmonary Dysplasia (BPD), Sepsis, and Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS).

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on AVR-25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVR-25.

Explore the full profile